Increases in PULS Cardiac Test scores after mRNA vaccinations suggest a significantly higher risk of developing acute coronary syndrome, according to findings presented at AHA 2021.
Researchers evaluated the safety and efficacy of sonothrombolysism, an ultrasound-enhanced thrombolysis, in patients with acute ischemic stroke with large vessel occlusion in randomized controlled clinical trials.
Major adverse cardiopulmonary outcomes not reduced with aspirin, apixaban versus placebo for clinically stable COVID-19 outpatients.
Reduction in venous thromboembolism, arterial thromboembolism, and deaths seen in high-risk patients in non-ICU, but not ICU, settings.
The clinical performance of several scores to predict VTE risk in the setting of malignancy are compared in a study.
Compared with other DOACs, rivaroxaban linked to higher rates of GI bleeding overall and in an analysis restricted to patients with atrial fibrillation.
Overall, 92.3 percent of patients had plasma D-dimer levels ≥0.05 µg/mL, including all with and 91.2 percent without, pulmonary embolism.
Long-term risks and consequences are considerable for patients receiving VKA, DOAC after first unprovoked VTE.
Researchers characterized incidence and factors linked to cerebral venous thrombosis associated with myeloproliferative neoplasms.
The authors review 8 cases of thrombosis in uncommon sites caused by protein S deficiency.
